IQVIA HOLDINGS INC. (IQV)
About IQVIA HOLDINGS INC.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $16.3B
- Net income
- $1.4B
- Total assets
- $29.9B
- Market cap
- $30.6B
- Operating margin
- 13.4%
- Net margin
- 8.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $16.3B
- Operating expenses
- $14.1B
- Operating income
- $2.2B
- Income tax
- $252.0M
- Net income
- $1.4B
- EPS (basic)
- $7.91
- EPS (diluted)
- $7.84
Balance sheet
- Total assets
- $29.9B
- Current assets
- $6.2B
- Total liabilities
- $23.3B
- Current liabilities
- $8.3B
- Shareholders’ equity
- $6.6B
Cash flow
- Operating cash flow
- $2.7B
- Investing cash flow
- -$2.3B
- Financing cash flow
- -$150.0M
- Net cash flow
- $278.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $30.6B
- P/E ratio
- 26.5
- EPS (diluted)
- $7.84
- Shares outstanding
- 147.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2013
Iqvia Holdings Inc. (IQV) Stock Price
- Profitable — net income of $1.4B in FY2025.
- Revenue grew 18% from FY2021 to FY2025.
- Trading 15% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 26.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IQVIA HOLDINGS INC..
Write a review
News about IQVIA HOLDINGS INC.
News & sentiment via Polygon.io
Iqvia Holdings Inc.: frequently asked questions
Is Iqvia Holdings Inc. an American company?
Yes — Iqvia Holdings Inc. is an American company headquartered in Durham, North Carolina. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Iqvia Holdings Inc. headquartered?
Iqvia Holdings Inc. is headquartered in Durham, North Carolina, United States.
Is Iqvia Holdings Inc. publicly traded?
Yes — Iqvia Holdings Inc. is a publicly traded company. Its stock trades under the ticker symbol IQV on the NYSE.
What does Iqvia Holdings Inc. do?
Iqvia Holdings Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
